Ola A Harb1, Mariem A Elfeky2, Basant Sh El Shafaay3, Heba F Taha4, Gamal Osman5, Ibtsam Shehta Harera6, Loay M Gertallah7, Doaa Metwaly Abdelmonem8, Ahmed Embaby9. 1. Department of Pathology, Zagazig University, Faculty of Medicine, Zagazig, Egypt. Electronic address: oahmd@zu.edu.eg. 2. Department of Pathology, Zagazig University, Faculty of Medicine, Zagazig, Egypt. Electronic address: Mariemelfeky@gmail.com. 3. Department of Clinical Oncology and Nuclear Medicine, Faculty of Medicine, Zagazig, Egypt. Electronic address: Basantshaaban@Gmail.com. 4. Department of Medical Oncology, Faculty of Medicine, Zagazig, Egypt. Electronic address: hebafekry144@yahoo.com. 5. Department of General surgery, Faculty of Medicine, Zagazig University, Zagazig, Egypt. Electronic address: gamalosman_20@hotmail.com. 6. Department of General surgery, Faculty of Medicine, Zagazig University, Zagazig, Egypt. Electronic address: dribtsamharera@yahoo.com. 7. Department of General surgery, Faculty of Medicine, Zagazig University, Zagazig, Egypt. Electronic address: loayelhady@gmail.com. 8. Department of Clinical Pathology, Faculty of Medicine, Zagazig University, Zagazig, Egypt. Electronic address: Doaametwaly2005@yahoo.com. 9. Department of Internal Medicine, Faculty of Medicine, Zagazig University, Zagazig, Egypt. Electronic address: Dr.embaby@yahoo.com.
Abstract
BACKGROUND: Clear cell renal cell carcinoma (cc-RCC), is a serious cancer regarding; its fatality, liability for metastases and chemoresistance, so identification of recent therapeutic targets to improve the patients prognosis is needed. SPOP is a BTB/POZ domain containing speckle-type POZ protein, has been identified as an E3 ubiquitin ligase component. ZEB1 is an essential epithelial mesenchymal transition (EMT) activator; E-cadherin is a cell adhesion protein that had been detected in normal epithelial cells membrane. AIM: Was to assess the tissue protein markers SPOP, ZEB1 & E-cadherin expressions in benign areas of neoplastic kidney specimens and in cc-RCC patients, then correlating their expression levels with patients clinicopathological and prognostic data. METHODS: We evaluated SPOP, ZEB-1 & E-cadherin expression using immunohistochemistry in samples from 50 cc-RCC and 20 benign areas of neoplastic kidney specimens, then we followed our patients for 5 years and finally we have analyzed correlations between the levels of markers expressions with patients clinicopathological and prognostic criteria in cc-RCC. RESULTS: Positive expression of SPOP & ZEB1 in addition to negative E- cadherin expression was detected in cc-RCC more than benign areas of neoplastic kidney specimens (p = 0.004 and p < 0.001 respectively). In cc-RCC Positive expression of SPOP, ZEB1 and negative E- cadherin expression was associated with higher grade (p = 0.006, 0.007 & <0.001 respectively), advanced AJCC stage (p = 0.013, 0.023 & <0.001 respectively), presence of L.N metastases (p = 0.002 = 0.010 and <0.001 respectively), distant metastases (p = 0.001, 0.003 & 0.035 respectively), poor PFS and OS rates (p < 0.001 and p = 0.013 respectively). CONCLUSION: Positive expression of SPOP& ZEB1 in addition to negative E- cadherin are associated with poor prognosis in cc-RCC patients.
BACKGROUND:Clear cell renal cell carcinoma (cc-RCC), is a serious cancer regarding; its fatality, liability for metastases and chemoresistance, so identification of recent therapeutic targets to improve the patients prognosis is needed. SPOP is a BTB/POZ domain containing speckle-type POZ protein, has been identified as an E3 ubiquitin ligase component. ZEB1 is an essential epithelial mesenchymal transition (EMT) activator; E-cadherin is a cell adhesion protein that had been detected in normal epithelial cells membrane. AIM: Was to assess the tissue protein markers SPOP, ZEB1 & E-cadherin expressions in benign areas of neoplastic kidney specimens and in cc-RCC patients, then correlating their expression levels with patients clinicopathological and prognostic data. METHODS: We evaluated SPOP, ZEB-1 & E-cadherin expression using immunohistochemistry in samples from 50 cc-RCC and 20 benign areas of neoplastic kidney specimens, then we followed our patients for 5 years and finally we have analyzed correlations between the levels of markers expressions with patients clinicopathological and prognostic criteria in cc-RCC. RESULTS: Positive expression of SPOP & ZEB1 in addition to negative E- cadherin expression was detected in cc-RCC more than benign areas of neoplastic kidney specimens (p = 0.004 and p < 0.001 respectively). In cc-RCC Positive expression of SPOP, ZEB1 and negative E- cadherin expression was associated with higher grade (p = 0.006, 0.007 & <0.001 respectively), advanced AJCC stage (p = 0.013, 0.023 & <0.001 respectively), presence of L.N metastases (p = 0.002 = 0.010 and <0.001 respectively), distant metastases (p = 0.001, 0.003 & 0.035 respectively), poor PFS and OS rates (p < 0.001 and p = 0.013 respectively). CONCLUSION: Positive expression of SPOP& ZEB1 in addition to negative E- cadherin are associated with poor prognosis in cc-RCC patients.
Authors: Yulian Mytsyk; Yuriy Borys; Lesia Tumanovska; Dmytro Stroy; Askold Kucher; Katarina Gazdikova; Luis Rodrigo; Peter Kruzliak; Robert Prosecky; Peter Urdzik; Victor Dosenko Journal: Clin Exp Med Date: 2019-08-22 Impact factor: 3.984
Authors: Eike Burandt; Felix Lübbersmeyer; Natalia Gorbokon; Franziska Büscheck; Andreas M Luebke; Anne Menz; Martina Kluth; Claudia Hube-Magg; Andrea Hinsch; Doris Höflmayer; Sören Weidemann; Christoph Fraune; Katharina Möller; Frank Jacobsen; Patrick Lebok; Till Sebastian Clauditz; Guido Sauter; Ronald Simon; Ria Uhlig; Waldemar Wilczak; Stefan Steurer; Sarah Minner; Rainer Krech; David Dum; Till Krech; Andreas Holger Marx; Christian Bernreuther Journal: Biomark Res Date: 2021-06-05